礼来的CGRP单抗Emgality用于预防偏头痛的晚期临床试验成功

2019-08-07 不详 MedSci原创

Eli Lilly宣布,在最近的CONQUER试验中,Emgality(galcanezumab-gnlm)用于预防慢性和偶发性偏头痛,符合主要和所有关键的次要结果。Emgality靶向阻断降钙素基因相关肽(CGRP)受体,该受体在偏头痛的发生中发挥了关键作用。

Eli Lilly宣布,在最近的CONQUER试验中,Emgality(galcanezumab-gnlm)用于预防慢性和偶发性偏头痛达到了实验终点。Emgality靶向阻断降钙素基因相关肽(CGRP)受体,该受体在偏头痛的发生中发挥了关键作用。

该研究评估了由于功效不足或出于安全性/耐受性原因而在两到四种不同的标准护理偏头痛预防药物类别使用失败的患者中Emgality的作用。

CONQUER试验是一项在12个国家进行的III期双盲全球研究,共纳入462例慢性或偶发性偏头痛患者,这些患者有治疗失败的记录。患者基线水平为平均每月偏头痛13.2天,并且在筛选期和前瞻性基线期后,符合条件的患者按1:1随机分配至Emgality 120 mg /月或安慰剂,进行为期3个月的双盲治疗。在该研究中,Emgality治疗每月偏头痛日减少4.1天,而安慰剂组减少1.0天。

Lilly Bio-Medicines神经病学发展副总裁Gudarz Davar表示:"预防性治疗失败在偏头痛患者中很常见。CONQUER研究采用了严格标准,以确定招募患有多个偏头痛预防性治疗失败的慢性和偶发性偏头痛患者,目的是了解Emgality是否可能是有这种重大未满足需求的患者的有效选择。"

在所有偏头痛预防用药使用者中,超过40%的患者有既往预防性用药失败或转换治疗的病史。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936896, encodeId=c999193689689, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 18 08:26:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734641, encodeId=d49f1e34641b5, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Wed Apr 01 22:26:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820078, encodeId=5a5b18200e868, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed May 13 17:26:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951935, encodeId=234e19519359d, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Oct 03 12:26:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370962, encodeId=e8783e0962bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 08 21:50:50 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1936896, encodeId=c999193689689, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 18 08:26:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734641, encodeId=d49f1e34641b5, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Wed Apr 01 22:26:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820078, encodeId=5a5b18200e868, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed May 13 17:26:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951935, encodeId=234e19519359d, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Oct 03 12:26:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370962, encodeId=e8783e0962bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 08 21:50:50 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1936896, encodeId=c999193689689, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 18 08:26:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734641, encodeId=d49f1e34641b5, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Wed Apr 01 22:26:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820078, encodeId=5a5b18200e868, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed May 13 17:26:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951935, encodeId=234e19519359d, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Oct 03 12:26:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370962, encodeId=e8783e0962bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 08 21:50:50 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1936896, encodeId=c999193689689, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 18 08:26:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734641, encodeId=d49f1e34641b5, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Wed Apr 01 22:26:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820078, encodeId=5a5b18200e868, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed May 13 17:26:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951935, encodeId=234e19519359d, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Oct 03 12:26:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370962, encodeId=e8783e0962bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 08 21:50:50 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2019-10-03 gostraight
  5. [GetPortalCommentsPageByObjectIdResponse(id=1936896, encodeId=c999193689689, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 18 08:26:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734641, encodeId=d49f1e34641b5, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Wed Apr 01 22:26:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820078, encodeId=5a5b18200e868, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed May 13 17:26:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951935, encodeId=234e19519359d, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Oct 03 12:26:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370962, encodeId=e8783e0962bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 08 21:50:50 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2019-08-08 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛

美国食品和药物管理局批准Eli Lilly的非阿片类止痛药Emgality用于预防偏头痛。

欧洲批准Teva的CGRP单抗Ajovy用于治疗偏头痛

Teva的偏头痛药物Ajovy(fremanezumab)已获得欧盟委员会批准,用于预防每月至少有4个偏头痛日的成人偏头痛患者。